PolyPid licenses surgical infection prevention drug to Advanz
Israeli drug enhancement company PolyPid (Nasdaq: PYPD) these days announced that it has entered into an distinctive licensing agreement in Europe with United kingdom-based mostly specialty and medical center pharmaceutical business Advanz Pharma (formerly Concordia Healthcare Corp.) for its direct drug prospect, D-PLEX100 for the prevention of surgical website bacterial infections in belly and cardiac surgical procedures.




Connected Articles or blog posts




PolyPid raises $60m at 3rd IPO attempt







Under the conditions of the arrangement, PolyPid will obtain an upfront payment of up to $23.5 million. This contains an rapid payment of $2.6 million, up to $12.5 million contingent on beneficial top rated-line results of Defend I Stage 3 review and additional enhancement-similar milestones of up to $8.4 million.

Following commercialization, PolyPid will receive up to $89 million in sales-associated milestones. The firm will also source D-PLEX100 to Advanz Pharma for a transfer price tag and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties.

PolyPid CEO Dikla Czaczkes Akselbrad said, “Advanz Pharma’s know-how in promoting medical center-based therapies, mixed with its important sources and relationships in the region, will prove invaluable in expanding entry to D-PLEX100 and offering this a lot-essential remedy, if accredited, to clients. We are also in active conversations with several large and mid-dimensions potential strategic associates, all with major existence and expertise promoting in hospitals and running rooms, to potentially commercialize D-PLEX100 in added geographies.”

Advanz Pharma CEO Steffen Wagner extra, “We are pretty excited by the possible of D-PLEX100 to efficiently avert SSIs and make improvements to client outcomes. D-PLEX100 is expected to be an vital expansion driver for ADVANZ PHARMA. The collaboration with PolyPid is in line with our approach for the commercialization of specialty and medical center prescribed drugs in Europe.”

PolyPid a short while ago announced the completion of enrollment of its Shield I Section 3 research of D-PLEX100 for the prevention of SSIs in stomach surgical procedures, with best-line final results expected by the finish of the recent quarter.

PolyPid’s share value is up 3.19% on Nasdaq at $5.34, offering a market cap of $103.877 million.

Published by Globes, Israel organization news – en.globes.co.il – on August 3 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.


